Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
Clearmind Medicine Inc. announces a successful $7.5 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner, aimed at uplisting to NASDAQ. The company is dedicated to developing psychedelic-derived therapeutics, focusing on health challenges such as alcohol use disorder. Currently, Clearmind possesses four patent families and aims to expand its intellectual property portfolio. The funds from this offering will support research and regulatory commercialization of their compounds.
- Successfully raised $7.5 million through an underwritten public offering.
- Aiming for uplisting to NASDAQ, potentially increasing visibility and access to investors.
- Focus on developing psychedelic therapeutics aimed at addressing significant health issues.
- Possible shareholder dilution due to new stock issuance from the offering.
Insights
Analyzing...
NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
For more information, please visit the Company's website: https://www.clearmindmedicine.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/726714/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-75-Million-Underwritten-Public-Offering-Uplisting-for-Clearmind-Medicine-Inc-NASDAQ-CMND
FAQ
What is the purpose of Clearmind Medicine's $7.5 million public offering?
What health issues does Clearmind Medicine target with its products?
What is the significance of the uplisting for Clearmind Medicine?
Who acted as the bookrunner for Clearmind Medicine's public offering?
What are the potential risks for investors from this public offering?
